Novartis Pays $422M For Off-Label Marketing

From Pharmalot by Ed Silverman Another week, another drugmaker agrees to settle off-label marketing charges brought by the federal government. This time, Novartis will pay $422.5 million for illegally promoting its Trileptal epilepsy med for unapproved uses, such as bipolar disorder and neuropathic pain... Go here to read the full story. UPDATE 10/1/10: More on this story at Law.com and The Wall Street Journal Law Blog. UPDATE: 10/8/10: More on the story from AboutLawsuits.com